# ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

> **NCT05276609** · PHASE1 · UNKNOWN · sponsor: **Shanghai Hansoh Biomedical Co., Ltd** · enrollment: 177 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HS-20093 (Phase Ia: Dose escalation)
- **DRUG:** HS-20093 (Phase Ib: Dose expansion)

## Key facts

- **NCT ID:** NCT05276609
- **Lead sponsor:** Shanghai Hansoh Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-28
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276609, "ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05276609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*